Augoustides John G, Hosalkar Hetal H, O'Reardon John P, Kofke W Andrew, Datto Catherine J
Department of Anesthesia (Cardiothoracic Section), Hospital of University of Pennsylvania, Philadelphia, PA 19104-4283, USA.
J ECT. 2005 Jun;21(2):128-31. doi: 10.1097/01.yct.0000167463.71704.52.
We present a case of anesthesia for electroconvulsive (ECT) therapy that was complicated by emetic sensitivity to etomidate, fragile ictal threshold, and mild pseudocholinesterase deficiency. The anesthetic was designed in this patient taking all his issues in consideration. The mild pseudocholinesterase deficiency necessitated a (50-75%) reduction in succinylcholine dosage, careful monitoring of the train of four, and postictal amnestic coverage to prevent paralysis upon waking. The significant emetic response to etomidate prompted substitution to propofol and preemptive ondansetron. Propofol significantly raised the ictal threshold but significantly reduced the postprocedural emesis. Eventually, this clinical challenge was resolved with adjunctive use of low-dose etomidate and remifentanil. This combination preserved the ictal parameters, providing patient comfort, good clinical response, and therapeutic efficacy. Although seizure duration and quality often are restored with hyperventilation and caffeine, this case necessitated a return to etomidate for the restoration of satisfactory ictal parameters. Although this effect of remifentanil has been described with methohexital, and etomidate with alfentanil, to the best of our knowledge, this is the first reported case of adjunctive remifentanil with etomidate for preserving ictal threshold. The outpatient course of ECT was thus completed with all psychiatric and anesthetic goals satisfied: adequate seizure quality and duration, no paralysis upon waking, no post-ECT nausea and vomiting, and patient satisfaction. Anesthesiologists should be aware of factors influencing the seizure duration and, keeping in mind the coexisting medical conditions of the patient, adjustments should be made to get the best possible outcome.
我们报告一例电休克治疗(ECT)的麻醉病例,该病例因对依托咪酯的催吐敏感性、脆弱的发作阈值和轻度假性胆碱酯酶缺乏而变得复杂。针对该患者的所有问题,制定了麻醉方案。轻度假性胆碱酯酶缺乏使得琥珀酰胆碱剂量需要减少(50 - 75%),仔细监测四个成串刺激,并进行发作后遗忘覆盖以防止苏醒时出现麻痹。对依托咪酯显著的催吐反应促使改用丙泊酚并预防性使用昂丹司琼。丙泊酚显著提高了发作阈值,但显著减少了术后呕吐。最终,通过联合使用低剂量依托咪酯和瑞芬太尼解决了这一临床挑战。这种组合保留了发作参数,提供了患者舒适度、良好的临床反应和治疗效果。尽管通过过度通气和咖啡因通常可恢复癫痫发作持续时间和质量,但该病例需要再次使用依托咪酯以恢复令人满意的发作参数。尽管瑞芬太尼与美索比妥、依托咪酯与阿芬太尼的这种作用已被描述,但据我们所知,这是首例报道的联合使用瑞芬太尼和依托咪酯以保留发作阈值的病例。ECT的门诊疗程因此得以完成,所有精神科和麻醉目标均得以实现:癫痫发作质量和持续时间足够、苏醒时无麻痹、ECT后无恶心呕吐以及患者满意。麻醉医生应了解影响癫痫发作持续时间的因素,并牢记患者并存的医疗状况,应进行调整以获得最佳可能结果。